Buradasınız

Anasayfa » Content

L-CARNÎTÎN TEDAVİSİNİN HEMODİYALİZ VE PERİTON DİYALİZİ HASTALARINDA ERİTROSİT YAŞAM SÜRESİNE ETKİSİ

THE EFFECT OF L-CARNITINE TREATMENT ON ERYTHROCYTE SURVIVAL IN HEMODIALYSIS AND PERITONEAL DIALYSIS PATIENTS

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 1999

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Renal anemia improves after L-Carnitine (L-C) administration to patients on chronic dialysis due to causes that remain unclear. Our study was designed on dialysis patients to investigate effects of L-C on anemia and on erythrocyte survival (ES) which is important in anemia. This study consisted 15Hemodialysis (HD), 16 Continuous Ambulatory Peritoneal Dialysis (DAPD) patients and 44 healthy subjects. Patients received L-C 2 g /day for 4 months then 20-25 mg/kg 3 days a week, for following 12 months. At initial, after 4 and 16 months biochemically, and initial, after 6, 12 months ES were investigated. Initial free carnitine (FC) level in patients (was lower than that of controls and increased during 16 months. An increase in Haemoglobin -Hb, Hematocrit-Htc, Erythrocytes —Er was occurred 4 months after, and continued in following 12 months. ES was prolonged from 16±6 days to 22.6±10days in 6th and to 24.2±6 days in 12th months. In serum, Albumin (Alb) increased, creatinin decreased in 16th month in DAPD group. Alb increased , urea decreased n HD group. Our findings suggest that the improvement in anemia was mainly due to prolonged ES with L-C treatment. We also thought that L-C might has an effect on Hb sentesis.
Abstract (Original Language): 
L-C'amitine'in diyaliz hastalarındaki anemiyi düzeltici mekanizması tam açıklanamamıştır. Bu nedenle çalışmamızda, diyaliz hastalarında L-Carnitine tedavisinin anemi ve eritrosit yaşam süresi (EYS) üzerine etkilerini araştırdık. 15i Hemodiyaliz (HD), 16'sı Devamlı Ayaktan Periton Diyaliz (DAPD) tedavisi gören 31 hasta ve 44 sağlıklı birey çalışmaya alındı. Hasta gruplarına 4 ay 2gr/gün, izleyen 12 ay 20-25 mg/kg/haftada 3gün L-C (HD'de İ.V..DAPD de P.O.) uygulandı. Başlangıç, 4 , 16 ay sonra biyokimyasal ve başlangıç, 6, 12 ay sonra Cr-51 ile EYS incelemeler yapıldı. Başlangıçta kontrolden düşük olan Hemoglobin-Hb, Hematokrit -Htc, eritrosit -Er değerleri tedaviden 4 ve 16 ay sonra yükseldi. Kontrol grubundan (29.4±7 gün) düşük olan hasta EYS, 16±6 günden 6 ayda 22.6±10 ve 12 ayda %51 yükselişle 24.2±6 güne çıktı. DAPD'de kreatinin (sKr), HD grubunda üre düştü.Her ikigrubda serum albumin (Alb) ve total protein (t.prot) arttı. Kontrol grubundan düşük olan hasta gruplarının plazma free camilin (FC) değerleri belirgin derecede yükseldi Bulgularımız, L-C nin anemiyi düzeltici etkisinin öncelikle EYS'nin uzamasından kaynaklandığını göstermekte ve Hb sentezine etkisini düşündürmektedir.
FULL TEXT (PDF): 
PDF icon pdf_tndt_254.pdf

REFERENCES

References: 

1. Winearls CG. Historical review on the use of recombinant human erythropoietin in chronic renal failure. Nephrol Dial Transplant 1995; 10 (Suppl2):3-9.
2. Sunder-Plassmann G, Hod WH. Erythropoietin and
iron. Clin Nephrol 1997;47:141-157.
3. Hampers CL, Streiff R, Nathan DG, Snyder D, Merrill JP. Megaloblastic hematopoiesis in uremia and in patients on long term hemodialysis. N Engl J Med 1967;276:551-554.
4. Eschbach JW, Adamson JW, Cook JW. Disorders of red
blood cell production in uremia. Arch Intern Med 1970;
12:812-815.
5. Rao DS, Shih MS, Mohini R. Effect of serum
parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 1993;328:171-175.
6. Krantz SB. Pathogenesis and treatment of anemia of
chronic disease. Am J Med Sci 1994; 307:353-359.
7. Kaiser L, Schwartz KA. Aluminium-induced anemia.
Am J Kidney Dis 1985; 6(5):348-351.
8. Eschbach JW, Frank DJr, Adamson J, Kuhn I, Serbner BH, Fisnch CA. Erythropoiesis in patients with renal failure undergoing chronic dailysis. N Eng J Med 1967; 276:253-258.
9. Wanner C, Forstner-Wanner S, Rossle C, Furst P, Schollmeyer P, Hörl WH. Carnitine metabolism in patients with chronic renal failure: Effect of L-carnitine supplementation. Kidney International 1987; 32
(Suppl22):S132-S135.
10. Trovato GM, Ginardi V, Di Marco V, Dell'aira AE,
Corsi M. Long-term L-carnitine treatment of chronic anemia of patients with end-stage renal failure. Curr TherRes 1982; 31(6): 1042-1049.
11. Labonia WD, Morelli OH Jr, Gimenez Mİ, Freuler PU, Morelli OH. Effects of L-carnitin on sodium transport in erythrocytes from dialyzed uremic patients.
Kidney International 1987; 32:754-759.
12. Donatelli M, Terrizi G, Zummo G, Russo V, Bucalo ML, Scarpinato A. Effects of L-carnitine on chronic anemia and erythrocyte adenosine triphosphate concentration in hemodialysis patients. Curr Ther Res 1987;41(5):620-624.
13. Hoppel C. The physiological role of carnitine. In Ferrari
R, Dimaro S, Sherwood G eds. L-carnitine and its role in medicine: from function to therapy. Academic Pres
Ltd, London, 1992;5-21.
14. Borum Pr, Bennet SG. Carnitine as an essential
nutritient. J Am Coll Nutrition 1986; 5:177-182.
15. Guarnieri G, Toigo G, Crapesi L, et al. Carnitine metabolism in chronic renal failure. Contr Nephrol
1988;65:1-23.
16. Bellunghieri G, Savica V, Nallmace A, et al. Correlation between increased serum and tissue L-carnitine and improved muscle symptoms in hemodialyzed patients. Am J Clin Nutr 1983; 3:523¬531.
17. Gilbert Ef. Carnitine deficiency. Pathology 1985; 17:161-169.
18. Labonia WD. L-carnitine effect on anemia in hemodialyzed patients treated with erythropoietin. Am
J Kidney Dis 1995; 26(5): 757-764.
19. Berard E, Barrillon D, Iordache A, Bayle J, Cassuto-Viguier E. Low dose of L-carnitine impairs membrane fragility of erythrocytes in hemodialysis patients.
Nephron 1994; 68:145.
122
20. Matsumura M, Hatakeyama S, Kani I, Mabuchi H, Muramoto H,. Correlation between serum carnitine levels and erythrocyte osmotic fragility in hemodialysis patients. Nephron 1996; 72:574-578.
21. Kletzmayr J, Mayer G, Legenstein E, et al. Anemia and carnitine supplementation in hemodialyzed patients.
Kidney International 1999; SS (Suppl69):S93-S99.
22. Schwartz AB, Kahn SB, Kelch B, Kim KE, Pequignot E. RBC improved survival due to recombinant human erythropoietin explains effectiveness of less frequent low dose subcutaneous thereapy. Clin Nephrol 1992; 38(5): 283-289.
23. Polenakovic M, Sikole A. Is erythropoietin a survival factor for red blood cells? J Am Soc Nephrol 1996; 7(8): 1178-1182.
24. Yüksel M, Sen S, Belce A, et al. The effect of erythropoietin (EPO) treatment on red blood cell survival (RBCS), radical oxygen species (ROS) and antioxidants in dialysis patients (DPts). Nephrol Dial Transplant 1999; 14(9): A259 [abstract].
25. Sen S, Yüksel M, Gümüştaş K, et al. The effect of L-Carnitine on anemia, RBC survival, dyslipidemia, endothelial function in dialysis patients. Nephrol Dial
Transplant 1998; 13(6): A165 [abstract].
123

Thank you for copying data from http://www.arastirmax.com